Keenova Therapeutics reports record $543M Q1 revenue
Keenova Therapeutics (NYSE:MNK) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, marking its first full quarter as a combined branded therapeutics entity following the merger of Mallinckrodt and Endo.











